Expression of Mir-489-3p as an Effective Marker of Poor Prognosis in Patients with Non-small-cell Lung Carcinoma.
Academic Article
Overview
abstract
Context: Lung carcinoma accounts for the majority of cancer deaths, and its 5-year survival rate isn't optimistic. Remarkable progress has been made in recent decades toward understanding the biological behavior of non-small-cell lung carcinoma (NSCLC) and creating targeted molecular therapies for diagnosis and treatment. However, little literature is available on the topic, and the clinical significance and application of miR-489-3p for NSCLC can't yet be determined. Objective: The study intended to determine if miR-489-3p can predict prognosis for patients with NSCLC. Design: The research team designed a prospective study to examine in depth and analyze the molecular science of NSCLC tumors in a clinical setting. Setting: The study took place in the Department of the Special Ward at the Shanxi Provincial Cancer Hospital in Taiyuan, Shanxi, China. Participants: Participants were 116 patients with NSCLC at the hospital and 87 healthy people. Outcome Measures: A type of microRNA (miRNA), MiR-489-3p, was detected using nano-polymerase chain reaction (PCR). The diagnostic value of miR-489-3p for lung carcinoma and its predictive value for death from the disease were analyzed using a receiver operating characteristic (ROC) curve, and the three-year prognosis for patients was examined. Human NSCLC cell lines and normal, human, lung epithelial cells were obtained, and miR-489-3p was detected to assess the biological effects on lung-cancer cells. Results: MiR-489-3p has low expression in lung-cancer tissues, which indicates its good predictive value for prognosis for and death of lung-cancer patients. The activity of tumor cells increased after the inhibition of miR-489-3p. Conclusions: A low level of miR-489-3p indicates a poor prognosis for patients with NSCLC. A deeper understanding of the mechanism of miR-489-3p in lung carcinoma may be the key to the earlier diagnosis and treatment of lung carcinoma.
